HR
RGNX icon

Howe & Rusling’s Regenxbio RGNX Stock Holding History

Howe & Rusling’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-350
Closed -$20K – 873
2019
Q1 		$20K Buy
+350
New +$17.3K ﹤0.01% 380

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Howe & Rusling's RGNX Position: Q2 2019 in Review

Howe & Rusling sold out of Regenxbio (RGNX) in Q2 2019, closing a stake of 350 shares — an estimated $20K sold.

Howe & Rusling first reported a position in RGNX in Q1 2019 and held it in 1 quarter. The position peaked at $20K in Q1 2019. 186 funds tracked by Wall St. Rank hold RGNX as of Q2 2019.

  • Howe & Rusling reported no remaining Regenxbio position as of Q2 2019 after selling out during the quarter.
  • Howe & Rusling sold 350 Regenxbio shares in Q2 2019, an estimated $20K.
  • Howe & Rusling first reported a position in Regenxbio in Q1 2019 and held it in 1 quarter.
  • Howe & Rusling's Regenxbio position peaked at $20K in Q1 2019.
  • 186 funds tracked by Wall St. Rank held Regenxbio as of Q2 2019.

Based on Howe & Rusling's 13F filing for Q2 2019, filed 12 Aug 2019.